非小细胞肺癌化疗后脱氧核苷酸注射液干预对骨髓抑制的临床应用价

龙源期刊网 https://www.360docs.net/doc/e710905490.html,

非小细胞肺癌化疗后脱氧核苷酸注射液干预对骨髓抑制的临床应用价值的随机对照研究

作者:朱远东李丽赵永娟何丽娜

来源:《中国实用医药》2014年第34期

【摘要】目的探究非小细胞肺癌化疗后采用脱氧核苷酸治疗对骨髓抑制的临床应用价值。方法 47例非小细胞肺癌患者随机分为治疗组26例,对照组21例。均给予化疗,化疗周期内治疗组同时给予脱氧核苷酸注射液联合粒细胞集落刺激因子治疗;对照组仅给予粒细胞集落刺激因子皮下注射。评价化疗后7、21 d的白细胞、血小板、免疫功能、体重、生活质量评分及粒细胞集落刺激因子的不良反应。结果治疗组7 d后WBC计数为(5.6±1.5)×109/L,血小板计数为(84.2±16.2)×109/L, WBC恢复正常人数占92.3%,Ⅲ度+Ⅳ度骨髓抑制发生率为11.5%。对照组分别为(3.2±1.6)×109/L,(68.9±20.2)×109/L, 66.7%, 57.1%。两组比较差异具有统计学意义(P

【关键词】脱氧核苷酸;非小细胞肺癌;骨髓抑制

Randomized controlled trial of clinical application value of myelosuppression treated by deoxynucleotide injection intervention after chemotherapy for non small cell lung cancer ZHU Yuan-dong, LI Li, ZHAO Yong-juan,et al. Changzhou City the First People’s Hospital, Changzhou 213003, China

【Abstract】 Objective To explore the clinical application value of myelosuppression treated by deoxynucleotide after chemotherapy for non small cell lung cancer. Methods A total of 47 patients with non small cell lung cancer were randomly divided into treatment group with 26 cases and control group with 21 cases. Both groups received chemotherapy, while the treatment group received treatment deoxynucleotide injection combined with granulocyte colony-stimulating factor, and the control group received granulocyte colony-stimulating factor through subcutaneous injection. The evaluation was made on leukocyte, platelets, immune function, weight, life quality score, and adverse reaction of colony-stimulating factor in 7 d and 21 d after chemotherapy. Results In 7 d after chemotherapy, WBC score in the treatment group was (5.6±1.5)×109/L, the platelet count was (84.2±16.2)×109/L. Patients with normal WBC accounted for 92.3%, and the incidence of III+IV myelosuppression was 11.5%. These indexes in the control group were (3.2±1.6)×109/L,

(68.9±20.2)×109/L, 66.7%, and 57.1%. There was statistically significant difference between the two groups (P

【Key words】 Deoxynucleotide; Non small cell lung cancer; Myelosuppression

肺癌是最常见的恶性肿瘤之一,其中80%为非小细胞肺癌(NSCLC),确诊时大多数为中晚期,能手术的仅占少数,故化疗成为治疗中晚期非小细胞肺癌的主要手段之一[1]。化疗

相关文档
最新文档